口服水化与静脉水化预防慢性肾脏病IIIb期患者对比剂后急性肾损伤的比较:一项III期非劣效性研究(NICIR研究)
这项前瞻性随机III期非劣效性试验将264例IIIb期慢性肾脏病行择期增强CT的患者按1:1随机分配至口服水化组或静脉水化组,可评估各114例。口服水化组对比剂后急性肾损伤发生率为4.4%(95%CI 1.4-9.9%),静脉水化组为5.3%(95%CI 2.0-11.1%),持续性对比剂后急性肾损伤两组均为1.8%(95%CI 0.2-6.2%),无患者需透析或出现水化相关不良反应。作者结论为口服水化在预防对比剂后急性肾损伤方面不劣于静脉水化。
要点
- IIIb期慢性肾脏病患者择期增强CT前,口服水化预防对比剂后急性肾损伤不劣于静脉水化。
- 口服水化方案为检查前2小时饮水500 mL、检查后24小时内饮水2000 mL。
- 静脉水化方案为检查前1小时起碳酸氢钠(166 mmol/L)3 mL/kg/h,检查后第1小时1 mL/kg/h。
核心结论
- 在IIIb期慢性肾脏病择期增强CT患者中,口服水化预防对比剂后急性肾损伤不劣于静脉水化。
- 口服水化组对比剂后急性肾损伤发生率为4.4%(95%CI 1.4-9.9%),静脉水化组为5.3%(95%CI 2.0-11.1%)。
- 持续性对比剂后急性肾损伤两组均为1.8%(95%CI 0.2-6.2%),均无患者需透析或发生水化相关不良反应。
研究设计与样本
- 前瞻性、随机、III期、平行组、开放标签、非劣效性试验。
- 264例患者于2018年1月至2019年1月随机分组,口服水化组与静脉水化组各114例可评估。
- 所有患者接受100 mL非离子型碘对比剂行择期增强CT。
- 主要结局为增强CT后48-72小时内对比剂后急性肾损伤的发生比例。
诊断标准与关键数值
- 主要结局对比剂后急性肾损伤发生率:口服水化组4.4%(95%CI 1.4-9.9%)vs 静脉水化组5.3%(95%CI 2.0-11.1%)。
- 持续性对比剂后急性肾损伤发生率:口服水化组1.8%(95%CI 0.2-6.2%)vs 静脉水化组1.8%(95%CI 0.2-6.2%)。
- 口服水化方案:检查前2小时饮水500 mL,检查后24小时内饮水2000 mL。
- 静脉水化方案:碳酸氢钠(166 mmol/L)检查前1小时起3 mL/kg/h,检查后第1小时1 mL/kg/h。
临床应用与阅片要点
- 对IIIb期慢性肾脏病行择期增强CT的患者,口服水化可作为预防对比剂后急性肾损伤的水化方式。
- 口服水化方案为检查前2小时饮水500 mL、检查后24小时内饮水2000 mL。
- 两组持续性对比剂后急性肾损伤发生率均为1.8%,均无患者需透析或发生水化相关不良反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the non-inferiority of oral hydration compared to intravenous (i.v.) hydration in the prevention of post-contrast acute kidney injury (PC-AKI) in patients with stage IIIb chronic kidney disease (CKD) referred for an elective contrast-enhanced computed tomography (CE-CT).
MATERIAL AND METHODS: This is a prospective, randomized, phase 3, parallel-group, open-label, non-inferiority trial. Patients were randomly assigned 1:1 to receive prophylaxis against PC-AKI either with oral hydration: 500 mL of water two hours before and 2000 mL during the 24 h after performing CE-CT or i.v. hydration: sodium bicarbonate (166 mmol/L) 3 mL/kg/h starting one hour before and sodium bicarbonate (166 mmol/L) 1 mL/kg/h during the first hour after CE-CT. 100 mL of non-ionic iodinated contrast was administered in all cases. The primary outcome was the proportion of PC-AKI in the first 48-72 h after CE-CT. Secondary outcomes were persistent PC-AKI, the need for hemodialysis, and the occurrence of adverse events related to prophylaxis.
RESULTS: Of 264 patients randomized between January 2018 and January 2019, 114 received oral hydration, and 114 received i.v. hydration and were evaluable. No significant differences were found (p > 0.05) between arms in clinical characteristics or risk factors. PC-AKI rate was 4.4 % (95 %CI: 1.4-9.9 %) in the oral hydration arm and 5.3 % (95 %CI: 2.0-11.1%) in the i.v. hydration arm. The persistent PC-AKI rate was 1.8 % (95 %CI: 0.2-6.2 %) in both arms. No patient required dialysis during the first month after CE-CT or had adverse effects related to the hydration regime.
CONCLUSION: In those with stage IIIb CKD referred for an elective CE-CT, we provide evidence of non-inferiority of oral hydration compared to i.v. hydration in the prevention of PC-AKI.
引用
- Sebastià C, Páez-Carpio A, Guillen E, et al. Oral hydration compared to intravenous hydration in the prevention of post-contrast acute kidney injury in patients with chronic kidney disease stage IIIb: A phase III non-inferiority study (NICIR study). Eur J Radiol. 2021. PMID: 33516141. doi:10.1016/j.ejrad.2020.109509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。